Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Global Times.
Press releases published on March 19, 2025
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
GlobeNewswire
·
March 19, 2025
Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025 March 19, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA ( …
ONWARD Medical Schedules Reporting of Full Year 2024 Financial Results and Business Update Webcast
GlobeNewswire
·
March 19, 2025
EINDHOVEN, the Netherlands, March 19, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal …
Ipsen announces issuance of €500 million inaugural Rated Public Bond
GlobeNewswire
·
March 19, 2025
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced the successful completion of its …
Ipsen annonce le succès de son émission obligataire inaugurale notée d'un montant de 500 millions d'euros
GlobeNewswire
·
March 19, 2025
Cette transaction fait suite à l’attribution, par S&P et Moody’s, de notations de crédit ‘Investment Grade’ PARIS, FRANCE, 19 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, a annoncé aujourd'hui, le succès de …
Bedrock Forms Partnership with Pentabase to Target the Korean Market
GlobeNewswire
·
March 19, 2025
SEOUL, South Korea, March 19, 2025 (GLOBE NEWSWIRE) -- Bedrock, the world’s first multi-asset liquidity restaking protocol, has announced a partnership with Pentabase, a leading Web3 marketing firm in Korea. Entered into a partnership with Pentabase, a …
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
GlobeNewswire
·
March 19, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2 Phase II/ …